USES OF HER2 DIMERIZATION INHIBITOR PERTUZUMAB, AND ARTICLE OF MANUFACTURE INCLUDING PERTUZUMAB

摘要

To provide medicine for use in neoadjuvant therapy of estrogen receptor- and progesterone receptor-negative early-stage HER2-positive breast cancer.SOLUTION: The medicine includes pertuzumab, trastuzumab and carboplatin based chemotherapy. Estrogen receptor- and progesterone receptor-negative early-stage HER2-positive breast cancer has not spread beyond the breast or the axillary lymph nodes. The carboplatin-based chemotherapy comprises docetaxel and carboplatin.SELECTED DRAWING: None